Amanda Rosecrans1, Robert Harris2, Ronald E Saxton3, Margaret Cotterell2, Meredith Zoltick2, Catherine Willman2, Ingrid Blackwell2, Joy Bell2, Darryl Hayes2, Brian Weir4, Susan Sherman4, Gregory M Lucas3, Adena Greenbaum5, Kathleen R Page3. 1. Johns Hopkins University School of Medicine, 600 N. Wolfe St., Baltimore, MD, USA; Baltimore City Health Department, 1200 E. Fayette St., Baltimore, MD, USA. Electronic address: arosecr1@jhmi.edu. 2. Johns Hopkins University School of Medicine, 600 N. Wolfe St., Baltimore, MD, USA; Baltimore City Health Department, 1200 E. Fayette St., Baltimore, MD, USA. 3. Johns Hopkins University School of Medicine, 600 N. Wolfe St., Baltimore, MD, USA. 4. Johns Hopkins Bloomberg School of Public Health, 615 N. Wolfe, Baltimore, MD, USA. 5. Baltimore City Health Department, 1200 E. Fayette St., Baltimore, MD, USA.
Abstract
INTRODUCTION: In 2018, the Baltimore City Health Department launched a mobile clinic called Healthcare on The Spot, which offers low-threshold buprenorphine services integrated with health care services to meet the needs of people who use drugs. In addition to buprenorphine management, The Spot offers testing and treatment for hepatitis C, sexually transmitted infections, and HIV, as well as pre-exposure prophylaxis for HIV, wound care, vaccinations, naloxone distribution, and case management. METHODS AND MATERIALS: This cohort analysis includes clinical service data from the first 15 months of The Spot mobile clinic, from September 4, 2018, to November 23, 2019. The Spot co-located with the Baltimore syringe services program in five locations across the city. Descriptive data are provided for patient demographics and services provided, as well as percent of patients retained in buprenorphine treatment at one and three months. Logistic regression identified factors associated with retention at three months. RESULTS: The Spot mobile clinic provided services to 569 individuals from September 4, 2018, to November 23, 2019, including prescribing buprenorphine to 73.8% and testing to more than 70% for at least one infectious disease. Patients receiving a prescription for buprenorphine were more likely to be tested for HIV, hepatitis C, and sexually transmitted infections, as well as receive treatment for hepatitis C and preventive services including vaccination and naloxone distribution. The Spot initiated HIV treatment for four patients and HIV pre-exposure prophylaxis for twelve patients. More than 32% of patients had hepatitis C; nineteen of these patients initiated treatment for hepatitis C with eight having a documented cure. Buprenorphine treatment retention was 56.0% at one month and 26.2% at three months. Patients who were Black or receiving treatment for hepatitis C were more likely to be retained in buprenorphine treatment at three months. CONCLUSIONS: Increasing access to integrated medical services and drug treatment through low-threshold, community-based models of care can be an effective tool for addressing the effects of drug use.
INTRODUCTION: In 2018, the Baltimore City Health Department launched a mobile clinic called Healthcare on The Spot, which offers low-threshold buprenorphine services integrated with health care services to meet the needs of people who use drugs. In addition to buprenorphine management, The Spot offers testing and treatment for hepatitis C, sexually transmitted infections, and HIV, as well as pre-exposure prophylaxis for HIV, wound care, vaccinations, naloxone distribution, and case management. METHODS AND MATERIALS: This cohort analysis includes clinical service data from the first 15 months of The Spot mobile clinic, from September 4, 2018, to November 23, 2019. The Spot co-located with the Baltimore syringe services program in five locations across the city. Descriptive data are provided for patient demographics and services provided, as well as percent of patients retained in buprenorphine treatment at one and three months. Logistic regression identified factors associated with retention at three months. RESULTS: The Spot mobile clinic provided services to 569 individuals from September 4, 2018, to November 23, 2019, including prescribing buprenorphine to 73.8% and testing to more than 70% for at least one infectious disease. Patients receiving a prescription for buprenorphine were more likely to be tested for HIV, hepatitis C, and sexually transmitted infections, as well as receive treatment for hepatitis C and preventive services including vaccination and naloxone distribution. The Spot initiated HIV treatment for four patients and HIV pre-exposure prophylaxis for twelve patients. More than 32% of patients had hepatitis C; nineteen of these patients initiated treatment for hepatitis C with eight having a documented cure. Buprenorphine treatment retention was 56.0% at one month and 26.2% at three months. Patients who were Black or receiving treatment for hepatitis C were more likely to be retained in buprenorphine treatment at three months. CONCLUSIONS: Increasing access to integrated medical services and drug treatment through low-threshold, community-based models of care can be an effective tool for addressing the effects of drug use.
Authors: Tamara Beetham; Brendan Saloner; Sarah E Wakeman; Marema Gaye; Michael L Barnett Journal: Ann Intern Med Date: 2019-06-04 Impact factor: 25.391
Authors: Britton A Gibson; Jamie P Morano; Mary R Walton; Ruthanne Marcus; Alexei Zelenev; R Douglas Bruce; Frederick L Altice Journal: J Health Care Poor Underserved Date: 2017
Authors: Noa Krawczyk; Ramin Mojtabai; Elizabeth A Stuart; Michael Fingerhood; Deborah Agus; B Casey Lyons; Jonathan P Weiner; Brendan Saloner Journal: Addiction Date: 2020-02-24 Impact factor: 6.526
Authors: Elenore Patterson Bhatraju; Ellie Grossman; Babak Tofighi; Jennifer McNeely; Danae DiRocco; Mara Flannery; Ann Garment; Keith Goldfeld; Marc N Gourevitch; Joshua D Lee Journal: Addict Sci Clin Pract Date: 2017-02-28
Authors: Andrea J Low; Gitau Mburu; Nicky J Welton; Margaret T May; Charlotte F Davies; Clare French; Katy M Turner; Katharine J Looker; Hannah Christensen; Susie McLean; Tim Rhodes; Lucy Platt; Matthew Hickman; Andy Guise; Peter Vickerman Journal: Clin Infect Dis Date: 2016-06-25 Impact factor: 9.079
Authors: Louisa Degenhardt; Amy Peacock; Samantha Colledge; Janni Leung; Jason Grebely; Peter Vickerman; Jack Stone; Evan B Cunningham; Adam Trickey; Kostyantyn Dumchev; Michael Lynskey; Paul Griffiths; Richard P Mattick; Matthew Hickman; Sarah Larney Journal: Lancet Glob Health Date: 2017-10-23 Impact factor: 26.763
Authors: Robert Harris; Amanda Rosecrans; Meredith Zoltick; Catherine Willman; Ronald Saxton; Margaret Cotterell; Joy Bell; Ingrid Blackwell; Kathleen R Page Journal: Drug Alcohol Depend Date: 2021-11-26 Impact factor: 4.492